Physician profile
Ammar Wehbeh
NPI 1669461455
$773.66
in general payments reported to CMS, 2019-2025
15 companies · $47.05 in 2025
The $47.05 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $70.51 · 2021: $238 · 2022: $41.13 · 2024: $113 · 2025: $47.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.42 | 2019-2021 | |
| Abbvie INC. | $106.09 | 2020-2021 | |
| Novo Nordisk INC | $91.47 | 2020-2024 | Ozempic, Rybelsus |
| Amgen INC. | $55.19 | 2019 | |
| Abbott Laboratories | $52.33 | 2021-2025 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $40.48 | 2022-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $40.45 | 2021-2024 | Winrevair |
| Amarin Pharma, INC. | $34.19 | 2019 | |
| Genentech USA, INC. | $22.26 | 2021 | |
| Glaxosmithkline, LLC. | $17.85 | 2019 | |
| Lilly USA, LLC | $17.73 | 2021 | |
| Radius Health, INC. | $17.31 | 2024 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $16.12 | 2024 | |
| Mylan Pharmaceuticals INC. | $15.22 | 2021 | |
| Allergan, INC. | $13.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Wehbeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.